Debate around Juncker’s "dream team"
Enlarge image


Debate around Juncker’s "dream team"

02.10.2014 - New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

According to Juncker’s plan, the units in charge of medical devices and health technology will no longer belong to the health directorate DG Sanco, but rather to internal market directorate DG Enterprise and Industry. In addition, the European Medicines Agency, a London-based EU agency responsible for market authorisation of pharmaceutical products will now respond to both DG Sanco and DG Enterprise Industry, a controversial move that caused an outcry in the European Parliament last month. 

Juncker defended this decision and reassured his critics that “as president of the commission, I will make sure that public health will be at least as important in our policies as internal market considerations.” He explained: “Health technology products, cosmetics and medicinal products will be part of this new portfolio which is being entrusted to [Poland’s] Ms Elzbieta Bienkowska.” According to Juncker, he had to struggle for Bienkowska’s appointment and may have had to bolster her portfolio to arrange it – in direct response to the European Parliament’s request for more female commissioners. 

Starting on 29 September, Juncker’s newly proposed Commissioners have been presenting themselves and their proposals to Parliament. Vytenis Andriukaitis, the former Lithuanian health minister, will oversee public health and food safety issues. Members of the European Parliament have expressed concern that the EU could relax its rules on the use of antibiotics or hormones in livestock and of chlorine baths for poultry in light of EU-US trade talks. During the hearing Andriukaitis said, “As a doctor, I will say no to any attempt to lower EU standards. One cannot compromise on that. These standards shall not be sacrificed for free trade. The high EU standards have also facilitated our global exports.”

EU lawmakers have also questioned the nominee for Health and Food Safety on his stance on GM crops. GM crops are extensively grown in the Americas and Asia but face strong opposition in many EU states, including Germany and France.  “Cultivation of GMOs is a huge problem from a philosophical point of view. If we want to interfere with biodiversity, we have to be very vigilant and cautious.” Andriukaitis explained. 

The hearings will run until 7 October. On 22 October, Parliament will vote on whether to accept or reject Juncker’s proposed team. If accepted, the Commissioners will begin their work on 1 November.



30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.


26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.


25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.


23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.


19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.


18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.


15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.


12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.


11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

© 2007-2014 BIOCOM


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%


  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%


  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%


  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%


  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%


  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014